Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

They corrected the PR regarding Rolontis patient number.

CORRECTING and REPLACING Spectrum Pharmaceuticals Announces Detailed Results from Phase 3 Study of ROLONTIS® (eflapegrastim) Published in an ASCO Abstract
Business Wire Business Wire•May 17, 2018
HENDERSON, Nev.--(BUSINESS WIRE)--

Fourth paragraph, first sentence of release dated May 16, 2018, should read: “The ADVANCE study is a cornerstone in the ROLONTIS clinical program, which includes one Phase 2 and two Phase 3 clinical studies involving approximately 800 patients” (instead of “The ADVANCE study is a cornerstone in the ROLONTIS clinical program, which includes two Phase 3 clinical studies involving approximately 800 patients”).